Quanterix Corporation
QTRXHealthcareNASDAQMedical Devices · Last scanned Oct 26, 2026
Scan Results
Daily timeframeQuanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. With a market capitalization of $135.3M, it sits in micro-cap territory. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.
Market Cap
$135.3M
Beta
1.01
P/E (TTM)
—
P/E (Fwd)
-2.10
EPS (TTM)
$-2.66
EPS (Fwd)
$-1.36
ROE
-46.5%
ROA
-16.7%
Cash
$93.5M
Total Debt
$33.4M
Free CF
-$29.9M
52W Change
-49.6%
Annual Financials
Cash vs Debt
Where QTRX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, QTRX finished 16.57% below its 150-day moving average ($3.32) and 31.60% below its 200-day moving average ($4.05). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is QTRX overbought or oversold?
At the October 20, 2026 close, QTRX's RSI(14) was 26.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $93.5M in cash and $33.4M in debt, QTRX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$29.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -46.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $105.0M (2022) to $138.7M (2025), reflecting a 32% increase over the period.
With cash comfortably exceeding debt, QTRX has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Quanterix Corporation's trajectory.